Apoptosis, a morphologically distinct form of cell death observed during development, withdrawal of trophic hormones, and treatment with chemotherapeutic agents or cytotoxic cytokines, reflects the active participation of endogenous cellular proteases that help diassemble the cell. The present proposal seeks funds for collaborative studies by two laboratories with a long-standing interest in testing the central hypothesis that protease activation and activity plays an important role in the apoptotic process triggered by anticancer agents. Previous studies from these laboratories have demonstrated that 1) antineoplastic agents trigger apoptosis in a variety of cell types;2) the morphological changes of apoptosis are accompanied by the quantitative cleavage of a number of cellular polypeptides that is mediated by multiple aspartate-directed cysteine proteases (caspases) with differing substrate preferences;and 3) the process of caspase activation induced by cytotoxic cytokines can be inhibited when protein kinase C is activated by phorbol 12-myristate 13-acetate (PMA), which prevents recruitment of the adaptor molecule FADD to ligated death receptors. During the present funding period we demonstrated that the effects of PMA are selectively inhibited by PKC?1 siRNA, identified the death receptors Fas and DR5 as two polypeptides that are phosphorylated in a PMA-dependent manner, mapped phosphorylation sites on Fas, and showed that mutation of one of these abolished the effects of PMA on Fas-mediated apoptosis. In addition, we observed that downregulation of the antiapoptotic Bcl-2 family member Mcl-1 sensitizes cells to the death ligand TRAIL, an agent that was recently introduced into clinical testing. To build on these observations, we now propose to: 1) characterize the sites and biological significance of TRAIL receptor phosphorylation, 2) map the signal transduction pathway leading from PMA treatment to inhibition of death receptor-mediated apoptosis, and 3) perform preclinical studies to determine whether agents that affect death receptor pathway regulation can enhance TRAIL efficacy in tissue culture cell lines and clinical acute leukemia specimens. Collectively, these studies are designed to improve current understanding of the biology of death ligand-induced apoptosis and provide new information that should be helpful in designing more effective cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069008-15
Application #
7624253
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Arya, Suresh
Project Start
1995-04-01
Project End
2011-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
15
Fiscal Year
2009
Total Cost
$329,695
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Zhang, J-S; Herreros-Villanueva, M; Herreros-Vilanueva, M et al. (2014) Differential activity of GSK-3 isoforms regulates NF-?B and TRAIL- or TNF? induced apoptosis in pancreatic cancer cells. Cell Death Dis 5:e1142
Lee, S-H; Meng, X W; Flatten, K S et al. (2013) Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ 20:64-76
Gores, Gregory J; Kaufmann, Scott H (2012) Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 26:305-11
Gupta, Mamta; Hendrickson, Andrea E Wahner; Yun, Seong Seok et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119:476-87
Pang, Yuan-Ping; Dai, Haiming; Smith, Alyson et al. (2012) Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Sci Rep 2:257
Dai, Haiming; Smith, Alyson; Meng, X Wei et al. (2011) Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 194:39-48
Ding, Husheng; Hackbarth, Jennifer; Schneider, Paula A et al. (2011) Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 118:4872-81
Smith, Alyson J; Dai, Haiming; Correia, Cristina et al. (2011) Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286:17682-92
Schnepple, David J; Shepard, Brett; Bren, Gary D et al. (2011) Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem 286:35742-54
Meng, Xue Wei; Peterson, Kevin L; Dai, Haiming et al. (2011) High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem 286:35823-33

Showing the most recent 10 out of 84 publications